Skip to main content
Top
Published in: Psychiatric Quarterly 4/2017

01-12-2017 | Original Paper

Total Tau and Phosphorylated Tau Protein Serum Levels in Patients with Schizophrenia Compared with Controls

Authors: Ömer Faruk Demirel, Ihsan Cetin, Şenol Turan, Nazım Yıldız, Tarık Sağlam, Alaattin Duran

Published in: Psychiatric Quarterly | Issue 4/2017

Login to get access

Abstract

Tau protein is located in the axons of neurons and in Alzheimer Disease, is abnormally phosphorylated and aggregates into paired helical filaments (neurofibrillary tangles) reflecting the degree of neurofibrillary pathology and neurodegeneration. Although tau and phosphorylated tau (p-Tau) pathology is a hallmark for dementia, few studies were performed in patients of schizophrenia. This preliminary serum study was designed to compare serum total tau and p-Tau levels of schizophrenia patients with healthy controls. The study was included 42 patients diagnosed with schizophrenia and 42 healthy control subjects. Sociodemographic form was applied to both groups and PANSS was applied to patient group. Serum total tau and p-Tau levels were measured by ELISA method. Total tau and p-Tau levels of patients were significantly lower than healthy controls. There was a positive correlation between amount of past electroconvulsive therapies and total tau level. However total tau and p-Tau levels were positively correlated. Our study results showed that serum total tau and p-Tau levels of patients with schizophrenia were significantly lower than healthy controls.
Literature
1.
go back to reference Preuss U, Mandelkow EM: Mitotic phosphorylation of tau protein in neuronal cell lines resembles phosphorylation in Alzheimer’s disease. European Journal of Cell Biology 76:176–184, 1998.CrossRefPubMed Preuss U, Mandelkow EM: Mitotic phosphorylation of tau protein in neuronal cell lines resembles phosphorylation in Alzheimer’s disease. European Journal of Cell Biology 76:176–184, 1998.CrossRefPubMed
2.
go back to reference Schönknecht P, Pantel J, Hartmann T, Werle E, Volkmann M, Essig M et al: Cerebrospinal fluid tau levels in Alzheimer’s disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. Psychiatry Research 120:231–238, 2003.CrossRefPubMed Schönknecht P, Pantel J, Hartmann T, Werle E, Volkmann M, Essig M et al: Cerebrospinal fluid tau levels in Alzheimer’s disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. Psychiatry Research 120:231–238, 2003.CrossRefPubMed
3.
go back to reference Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J et al: Dynamics of gray matter loss in Alzheimer’s disease. Journal of Neuroscience 23:994–1005, 2003.PubMed Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J et al: Dynamics of gray matter loss in Alzheimer’s disease. Journal of Neuroscience 23:994–1005, 2003.PubMed
4.
go back to reference Frisoni, GB, Prestia A, Geroldi C, Adorni A, Ghidoni R, Amicucci G et al: Alzheimer’s CSF markers in older schizophrenia patients. International Journal of Geriatric Psychiatry 26:640–648, 2011.CrossRefPubMed Frisoni, GB, Prestia A, Geroldi C, Adorni A, Ghidoni R, Amicucci G et al: Alzheimer’s CSF markers in older schizophrenia patients. International Journal of Geriatric Psychiatry 26:640–648, 2011.CrossRefPubMed
5.
go back to reference Murray PS, Kirkwood CM, Gray MC, Fish KN, Ikonomovic MD, Hamilton RL et al: Hyperphosphorylated tau is elevated in Alzheimer's disease with psychosis. Journal of Alzheimer’s Disease 39:759–773, 2014.PubMedPubMedCentral Murray PS, Kirkwood CM, Gray MC, Fish KN, Ikonomovic MD, Hamilton RL et al: Hyperphosphorylated tau is elevated in Alzheimer's disease with psychosis. Journal of Alzheimer’s Disease 39:759–773, 2014.PubMedPubMedCentral
6.
go back to reference Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA et al: Heritability of psychosis in Alzheimer disease. American Journal of Geriatric Psychiatry 13:624–627, 2005.CrossRefPubMed Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA et al: Heritability of psychosis in Alzheimer disease. American Journal of Geriatric Psychiatry 13:624–627, 2005.CrossRefPubMed
7.
go back to reference Mukaetova-Ladinska EB, Harrington CR, Xuereb J, Roth M, Wischik CM: Biochemical, neuropathological, and clinical correlations of neurofibrillary degeneration in Alzheimer's disease. In: Bergener M, Finkel SI (Eds.) Treating Alzheimer's and other dementias: Clinical application of recent research advances. Springer, New York, pp 57–80, 1995. Mukaetova-Ladinska EB, Harrington CR, Xuereb J, Roth M, Wischik CM: Biochemical, neuropathological, and clinical correlations of neurofibrillary degeneration in Alzheimer's disease. In: Bergener M, Finkel SI (Eds.) Treating Alzheimer's and other dementias: Clinical application of recent research advances. Springer, New York, pp 57–80, 1995.
8.
go back to reference Schönknecht P, Hempel A, Hunt A, Seidl U, Volkmann M, Pantel J et al: Cerebrospinal fluid tau protein levels in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 253:100–102, 2003.PubMed Schönknecht P, Hempel A, Hunt A, Seidl U, Volkmann M, Pantel J et al: Cerebrospinal fluid tau protein levels in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 253:100–102, 2003.PubMed
9.
go back to reference Goldman AL, Pezawas L, Mattay VS, Fischl B, Verchinski BA, Zoltick B et al: Heritability of brain morphology related to schizophrenia: A large-scale automated magnetic resonance imaging segmentation study. Biological Psychiatry 63:475–483, 2008.CrossRefPubMed Goldman AL, Pezawas L, Mattay VS, Fischl B, Verchinski BA, Zoltick B et al: Heritability of brain morphology related to schizophrenia: A large-scale automated magnetic resonance imaging segmentation study. Biological Psychiatry 63:475–483, 2008.CrossRefPubMed
10.
go back to reference Tsuang M: Schizophrenia: genes and environment. Biological Psychiatry 47:210–220, 2000. Tsuang M: Schizophrenia: genes and environment. Biological Psychiatry 47:210–220, 2000.
11.
go back to reference American Psychiatric Association: Diagnostic and statistical manual of mental disorders, 5th edn. Arlington, VA: American Psychiatric Publishing, 2013.CrossRef American Psychiatric Association: Diagnostic and statistical manual of mental disorders, 5th edn. Arlington, VA: American Psychiatric Publishing, 2013.CrossRef
12.
go back to reference Kostakoğlu AE, Batur S, Tiryaki A, Gogus A: The reliability and validity of the Turkish version of positive and Negative syndrome scale (PANSS). Turkish Journal of Psychology 14:23–32, 1999. Kostakoğlu AE, Batur S, Tiryaki A, Gogus A: The reliability and validity of the Turkish version of positive and Negative syndrome scale (PANSS). Turkish Journal of Psychology 14:23–32, 1999.
13.
go back to reference Powchik P, Davidson M, Haroutunian V, Gabriel SM, Purohit DP, Perl DP et al: Postmortem studies in schizophrenia. Schizophrenia Bulletin 24:325–341, 1998.CrossRefPubMed Powchik P, Davidson M, Haroutunian V, Gabriel SM, Purohit DP, Perl DP et al: Postmortem studies in schizophrenia. Schizophrenia Bulletin 24:325–341, 1998.CrossRefPubMed
14.
go back to reference Anderson JE, O’Donnell BF, McCarley RW, Shenton ME: Progressive changes in schizophrenia: Do they exist and what do they mean? Restorative Neurology and Neuroscience 12:175–184, 1998.PubMed Anderson JE, O’Donnell BF, McCarley RW, Shenton ME: Progressive changes in schizophrenia: Do they exist and what do they mean? Restorative Neurology and Neuroscience 12:175–184, 1998.PubMed
15.
go back to reference Knoll JLT, Garver DL, Ramberg JE, Kingsbury SJ, Croissant D, McDermott B: Heterogeneity of the psychoses: Is there a neurodegenerative psychosis? Schizophrenia Bulletin 24:365–379, 1998.CrossRefPubMed Knoll JLT, Garver DL, Ramberg JE, Kingsbury SJ, Croissant D, McDermott B: Heterogeneity of the psychoses: Is there a neurodegenerative psychosis? Schizophrenia Bulletin 24:365–379, 1998.CrossRefPubMed
16.
go back to reference Kochunov P, Hong LE: Neurodevelopmental and neurodegenerative models of schizophrenia: White matter at the center stage. Schizophrenia Bulletin 40:721–728, 2014.CrossRefPubMedPubMedCentral Kochunov P, Hong LE: Neurodevelopmental and neurodegenerative models of schizophrenia: White matter at the center stage. Schizophrenia Bulletin 40:721–728, 2014.CrossRefPubMedPubMedCentral
17.
go back to reference Archer T, Ricci S, Garcia D, M.R. Ricciardi: Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders. Neurotoxicity Research 26:400–413, 2014.CrossRefPubMed Archer T, Ricci S, Garcia D, M.R. Ricciardi: Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders. Neurotoxicity Research 26:400–413, 2014.CrossRefPubMed
18.
go back to reference Jaworski J, Psujek M, Janczarek M, Szczerbo-Trojanowska M, Bartosik-Psujek H: Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy. Upsala Journal of Medical Sciences 117:284–292, 2012.CrossRefPubMedPubMedCentral Jaworski J, Psujek M, Janczarek M, Szczerbo-Trojanowska M, Bartosik-Psujek H: Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy. Upsala Journal of Medical Sciences 117:284–292, 2012.CrossRefPubMedPubMedCentral
19.
go back to reference Feinberg I: Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence? Journal of Psychiatric Research 17:319–334, 1982.CrossRefPubMed Feinberg I: Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence? Journal of Psychiatric Research 17:319–334, 1982.CrossRefPubMed
20.
go back to reference Pantelis C, Yücel M, Wood SJ, Velakoulis D, Sun D, Berger G et al: Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophria Bulletin 31:672–696, 2005.CrossRef Pantelis C, Yücel M, Wood SJ, Velakoulis D, Sun D, Berger G et al: Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophria Bulletin 31:672–696, 2005.CrossRef
21.
go back to reference Sun D, Phillips L, Velakoulis D, Yung A, McGorry PD, Wood SJ et al: Progressive brain structural changes mapped as psychosis develops in ‘at risk’ individuals. Schizophrenia Research 108:85–92, 2009.CrossRefPubMedPubMedCentral Sun D, Phillips L, Velakoulis D, Yung A, McGorry PD, Wood SJ et al: Progressive brain structural changes mapped as psychosis develops in ‘at risk’ individuals. Schizophrenia Research 108:85–92, 2009.CrossRefPubMedPubMedCentral
22.
go back to reference Zachrisson OC, Balldin J, Ekman R, Naesh O, Rosengren L, Agren H et al: No evident neuronal damage after electroconvulsive therapy. Psychiatry Research 30;96(2):157–165, 2000. Zachrisson OC, Balldin J, Ekman R, Naesh O, Rosengren L, Agren H et al: No evident neuronal damage after electroconvulsive therapy. Psychiatry Research 30;96(2):157–165, 2000.
23.
go back to reference Kranaster L, Aksay SS, Bumb JM, Janke C, Alonso A, Hoyer C, et al. Electroconvulsive therapy selectively enhances amyloid β 1-42 in the cerebrospinal fluid of patients with major depression: A prospective pilot study. European Neuropsychopharmacology 26(12):1877–1884, 2016.CrossRefPubMed Kranaster L, Aksay SS, Bumb JM, Janke C, Alonso A, Hoyer C, et al. Electroconvulsive therapy selectively enhances amyloid β 1-42 in the cerebrospinal fluid of patients with major depression: A prospective pilot study. European Neuropsychopharmacology 26(12):1877–1884, 2016.CrossRefPubMed
Metadata
Title
Total Tau and Phosphorylated Tau Protein Serum Levels in Patients with Schizophrenia Compared with Controls
Authors
Ömer Faruk Demirel
Ihsan Cetin
Şenol Turan
Nazım Yıldız
Tarık Sağlam
Alaattin Duran
Publication date
01-12-2017
Publisher
Springer US
Published in
Psychiatric Quarterly / Issue 4/2017
Print ISSN: 0033-2720
Electronic ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-017-9507-x

Other articles of this Issue 4/2017

Psychiatric Quarterly 4/2017 Go to the issue